Cassava Sciences Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Direxion Daily FTSE China Bull 3x Shares trades at $28.83. The key difference: Direxion Daily FTSE China Bull 3x Shares is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | YINN | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $56.62 |
52-Week Low | $0.87 | $21.45 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
YINN, a leveraged ETF tracking Chinese equities, trades at $29.20, down 9.6% in 24 hours amid bearish technical signals. Key support lies at $29, with resistance at $30–31. The fund's structure amplifies volatility, and financial ratios are unavailable due to its ETF nature. Recent news highlights China's AI investments and trade resilience, but geopolitical tensions and regulatory scrutiny persist.
Outlook remains cautious due to leverage risks and China's economic uncertainties. Opportunities exist if Hang Seng rebounds, but investors face elevated volatility from US-China frictions and ETF decay. Risks outweigh near-term catalysts, warranting careful position sizing.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →